Biopharmx Corp (NASDAQ:BPMX) shares traded up 6.3% on Friday . The company traded as high as $0.31 and last traded at $0.31. 542,089 shares changed hands during trading, a decline of 21% from the average session volume of 689,788 shares. The stock had previously closed at $0.29.

A number of research analysts have recently weighed in on the stock. Roth Capital set a $3.00 target price on shares of Biopharmx Corp and gave the company a “buy” rating in a research report on Saturday, June 3rd. HC Wainwright set a $3.00 target price on shares of Biopharmx Corp and gave the company a “buy” rating in a research report on Thursday, June 15th. Finally, Maxim Group reissued a “buy” rating and set a $3.00 target price on shares of Biopharmx Corp in a research report on Friday, June 2nd.

The firm’s market cap is $22.61 million. The company’s 50 day moving average price is $0.31 and its 200 day moving average price is $0.48.

Biopharmx Corp (NASDAQ:BPMX) last announced its quarterly earnings results on Wednesday, September 13th. The company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). Biopharmx Corp had a negative net margin of 28,405.26% and a negative return on equity of 1,847.04%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. On average, equities analysts predict that Biopharmx Corp will post ($0.25) earnings per share for the current fiscal year.

In other Biopharmx Corp news, major shareholder Franklin Resources Inc bought 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was bought at an average cost of $0.34 per share, for a total transaction of $85,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu KCG Holdings LLC grew its position in Biopharmx Corp by 366.2% during the second quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock valued at $241,000 after buying an additional 395,424 shares during the period. Vanguard Group Inc. grew its position in Biopharmx Corp by 324.6% during the second quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock valued at $927,000 after buying an additional 1,478,338 shares during the period. Finally, Vivo Capital LLC grew its position in Biopharmx Corp by 10.0% during the second quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock valued at $6,752,000 after buying an additional 1,282,052 shares during the period.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/15/biopharmx-corp-bpmx-trading-6-3-higher.html.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.